Beta-2 microglobulin is a strong prognostic factor in patients with DLBCL receiving R-CHOP therapy
Beta-2 microglobulin is a strong prognostic factor in patients with DLBCL receiving R-CHOP therapy
复制标题
DOI：
10.1016/j.leukres.2015.08.016
复制
发表时间：
2015-11-01
影响因子：
2.7
通讯作者：
Ishigatsubo, Yoshiaki
中科院分区：
文献类型：
--
作者：
Miyashita, Kazuho;Tomita, Naoto;Ishigatsubo, Yoshiaki
弥漫性大B细胞淋巴瘤（DLBCL）患者有用的预后标志物已被报道。为了确定哪种生物标志物最能预测DLBCL患者的预后，我们进行了一项回顾性研究，其中包括2003年至2012年期间接受利妥昔单抗，环磷酰胺，多柔比星，长春新碱和泼尼松龙（R-CHOP）治疗的319例DLBCL患者。我们以无进展生存期（PFS）为终点，评估了6种生物标志物[乳酸脱氢酶、可溶性白细胞介素2受体、胸苷激酶活性、β 2微球蛋白（B2 M）、C反应蛋白和铁蛋白]的预后意义和代表性临床特征。研究组包括181名男性和138名女性，中位年龄为63岁（范围：22-89岁）。在多变量分析中，血清B2 M水平与PFS最强相关（风险比，2.11;P=0.04）。在单变量分析中，血清B2 M水平>1.75 μ g/mL的患者（n = 210）的3年PFS率（71.2%）低于B2 M水平的患者
Useful prognostic markers for patients with diffuse large B cell lymphoma (DLBCL) have been reported. To identify which biomarker best predicts the prognosis of patients with DLBCL, we performed a retrospective study that included 319 DLBCL patients who had received rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) therapy between 2003 and 2012. We assessed the prognostic significance of six biomarkers [lactate dehydrogenase, soluble interleukin-2 receptor, thymidine kinase activity, beta-2 microglobulin (B2M), C-reactive protein, and ferritin] and representative clinical characteristics using progression-free survival (PFS) as the endpoint. The study group included 181 men and 138 women with a median age of 63 years (range, 22-89 years). In a multivariate analysis, the serum B2M level most strongly correlated with PFS (hazard ratio, 2.11;P=0.04). In a univariate analysis, patients with serum B2M levels >1.75 mu g/mL (n = 210) had a worse 3-year PFS rate (71.2%) than those with B2M levels